C-suite barometer: life sciences and pharmaceuticals sector view

Download the full report

Featuring commentary from our Forvis Mazars experts and contributors including Damien Catoir, Servier, and Cédric Moreau, Sofinnova Partners, the report provides a valuable benchmark for sector players looking to navigate a rapidly-evolving landscape.

What is striking about this year's findings is the high level of optimism in the life sciences and pharmaceuticals sector, with 98% of C-suite leaders indicating a positive growth outlook for their businesses in 2025. What is behind such optimism are robust drug pipelines and significant investments in R&D, allowing the sector to grow revenues that put it in a strong position to support future growth ambitions.

Nigel Layton Partner - Head of Pharma & Life Sciences

Key findings 

• Most leaders (96%) report growth, with a clear majority also boasting growing revenues, eleven points higher than others globally.
• Increased competition (55%) and supply chain restrictions (47%) are listed as the top factors holding back growth for C-suite executives.
• Economic factors were identified as having the biggest impact on businesses by 39% of leaders, with 37% viewing the emergence of technologies as significant.
• Two in three firms in the sector (67%) are boosting investment, averaged across all business activities.

Looking ahead, executives have outlined three core strategic priorities for 2025 and beyond: entering new products and services, transformation through company IT and technology, and international expansion.

Explore the full findings and discover how sector leaders are preparing for growth in a complex and competitive environment.